ALEXION PHARMACEUTICALS, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05578846
- Locations
- πΊπΈ
Baltimore Parexel EPCU, Baltimore, Maryland, United States
Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05565092
- Locations
- πΊπΈ
Research Site, Indianapolis, Indiana, United States
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT05556096
- Locations
- π¬π§
Research Site, Sheffield, United Kingdom
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05501717
- Locations
- π¬π§
Clinical Trial Site, Harrow, United Kingdom
π¬π§Research Site, Harrow, United Kingdom
Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05428696
- Locations
- π¬π§
Clinical Trial Site, Belfast, United Kingdom
Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05396742
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05389449
- Locations
- π¬π§
Research Site, London, United Kingdom
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05346354
- Locations
- πͺπΈ
Research Site, Esplugues de Llobregat, Spain
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319912
- Locations
- πΊπΈ
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- πΊπΈ
Clinical Trial Site, Lincoln, Nebraska, United States
Β© Copyright 2024. All Rights Reserved by MedPath